Evidence map›Paper›PMID 37344839›Full record

ReviewJournal of nanobiotechnology2023

Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures.

Jia Wang, Qingpeng Xie, Haoyue Song, Xiaohang Chen, Xiaoxuan Zhang, Xiangyu Zhao, Yujia Hao, Yuan Zhang, Huifei Li, Na Li and 2 more

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jia Wang *Shanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Qingpeng Xie *Shanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Haoyue SongShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Xiaohang ChenShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Xiaoxuan ZhangShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Xiangyu ZhaoShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Yujia HaoShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Yuan ZhangShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Huifei LiShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Na LiShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China.
Kelong FanCAS Engineering Laboratory for Nanozyme, Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China. fankelong@ibp.ac.cn.
Xing WangShanxi Medical University School and Hospital of Stomatology, Taiyuan, 030001, China. kqwx100@163.com.

Funding

the Project of Shanxi Province Key Laboratory of Oral Diseases Prevention and New Materials RC2021-02the Shanxi Applied Basic Research Program Outstanding Youth Cultivation Project Fund 202203021223006This work was supported by National Natural Science Foundation of China 82071155
6 · The paper itself

Abstract

The emergence of human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses significant challenges to global public health. Despite the extensive efforts of researchers worldwide, there remains considerable opportunities for improvement in timely diagnosis, specific treatment, and effective vaccines for SARS-CoV-2. This is due, in part, to the large number of asymptomatic carriers, rapid virus mutations, inconsistent confinement policies, untimely diagnosis and limited clear treatment plans. The emerging of nanozymes offers a promising approach for combating SARS-CoV-2 due to their stable physicochemical properties and high surface areas, which enable easier and multiple nano-bio interactions in vivo. Nanozymes inspire the development of sensitive and economic nanosensors for rapid detection, facilitate the development of specific medicines with minimal side effects for targeted therapy, trigger defensive mechanisms in the form of vaccines, and eliminate SARS-CoV-2 in the environment for prevention. In this review, we briefly present the limitations of existing countermeasures against coronavirus disease 2019 (COVID-19). We then reviewed the applications of nanozyme-based platforms in the fields of diagnostics, therapeutics and the prevention in COVID-19. Finally, we propose opportunities and challenges for the further development of nanozyme-based platforms for COVID-19. We expect that our review will provide valuable insights into the new emerging and re-emerging infectious pandemic from the perspective of nanozymes.

Indexed as

COVID-19VaccinesCOVID-19 TestingCOVID-19 VaccinesHumansPandemicsSARS-CoV-2COVID-19 VaccinesVaccinesCOVID-19NanomedicineNanozymesSARS-CoV-2

Identifiers

PMID37344839
PMCPMC10283317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.